Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D King

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Biochimica Et Biophysica Acta|October 31, 1998
UDP-glucuronosyltransferases in human intestinal mucosaA Radominska-Pandya, J M Little, J T Pandya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1997
Glucuronidation of retinoids by rat recombinant UDP: glucuronosyltransferase 1.1 (bilirubin UGT)A Radominska, J M Little, P A Lehman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 1998
Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7Z Cheng, G R Rios, C D King, et al.
The Journal of Clinical Investigation|March 21, 1998
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomesL Iyer, C D King, P F Whitington, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 13, 2006
HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126E M Lenz, R A D'Souza, A C Jordan, et al.
Nature Communications|June 22, 2022
Dissociation between individual differences in self-reported pain intensity and underlying fMRI brain activationM E Hoeppli, H Nahman-Averbuch, W A Hinkle, et al.
Journal of Clinical Pharmacology|November 24, 2011
Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2G Bain, C D King, J Brittain, et al.
Nature Communications|September 10, 2024
Reply to: Interindividual differences in pain can be explained by fMRI, sociodemographic, and psychological factorsM E Hoeppli, H Nahman-Averbuch, W A Hinkle, et al.
Journal of the Association for Research in Otolaryngology : JARO|September 11, 2001
Consequences of neural asynchrony: a case of auditory neuropathyN Kraus, A R Bradlow, M A Cheatham, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Modifications to the gut microbiome alter bone matrix proteomics and fracture toughness at the cellular scaleN K Hunt, C Liu, J Liu, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Biochimica Et Biophysica Acta|October 31, 1998
UDP-glucuronosyltransferases in human intestinal mucosaA Radominska-Pandya, J M Little, J T Pandya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1997
Glucuronidation of retinoids by rat recombinant UDP: glucuronosyltransferase 1.1 (bilirubin UGT)A Radominska, J M Little, P A Lehman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 1998
Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7Z Cheng, G R Rios, C D King, et al.
The Journal of Clinical Investigation|March 21, 1998
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomesL Iyer, C D King, P F Whitington, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 13, 2006
HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126E M Lenz, R A D'Souza, A C Jordan, et al.
Nature Communications|June 22, 2022
Dissociation between individual differences in self-reported pain intensity and underlying fMRI brain activationM E Hoeppli, H Nahman-Averbuch, W A Hinkle, et al.
Journal of Clinical Pharmacology|November 24, 2011
Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2G Bain, C D King, J Brittain, et al.
Nature Communications|September 10, 2024
Reply to: Interindividual differences in pain can be explained by fMRI, sociodemographic, and psychological factorsM E Hoeppli, H Nahman-Averbuch, W A Hinkle, et al.
Journal of the Association for Research in Otolaryngology : JARO|September 11, 2001
Consequences of neural asynchrony: a case of auditory neuropathyN Kraus, A R Bradlow, M A Cheatham, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Modifications to the gut microbiome alter bone matrix proteomics and fracture toughness at the cellular scaleN K Hunt, C Liu, J Liu, et al.
Pageof 5